Recent News

BTK Inhibitor Zanubrutinib Under Study in the Treatment of Resistant DLBCL

Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL

Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging

CD20-CD3 Bispecific Antibody Under Study in Resistant B-Cell Non-Hodgkin Lymphoma

Can ctDNA Analysis Be Used to Predict Outcomes in High-Risk DLBCL?

AKT Inhibitor Capivasertib Focus of Phase II Trial in B-Cell NHL

AACR 2022: Investigational BCL2 Inhibitors Demonstrate Varying Levels of Antilymphoma Activity

AACR 2022: Pharmacologic Attributes of Axicabtagene Ciloleucel and Therapeutic Index in Lymphoma

AACR 2022: Novel Microtubule-Targeting Agent Demonstrates Antilymphoma Activity

AACR 2022: Can BCL2 Family Protein Dephosphorylation Resensitize Venetoclax-Induced Apoptosis?

AACR 2022: Impact of PRMT5 Inhibition on BH3 Mimetic Sensitivity in Mantle Cell Lymphoma

AACR 2022: Predicting Response/Resistance to Brexucabtagene Autoleucel in Mantle Cell Lymphoma

AACR 2022: Can Decitabine Sensitize DLBCL Cells to Venetoclax?

Adding EP4 Receptor Agonists to CD20 Antigen Therapy in B-Cell Malignancies

Axicabtagene Ciloleucel Receives FDA Approval in Large B-Cell Lymphoma

Predicting Tolerability to Immunochemotherapy in DLBCL: Novel Tool Under Study

Using Targeted Induction Therapy to Minimize Chemotherapy Exposure in Mantle Cell Lymphoma

FDA Brief: Epcoritamab Granted Orphan Drug Designation in Follicular Lymphoma

Phase I Dose-Escalation Study of Mosunetuzumab in B-Cell Lymphomas

New ROR1-Targeting Antibody-Drug Conjugate Under Study in Treatment of Lymphoid Cancers

Aberrations of TP53 and Associated Outcomes With Immunotherapy for LBCL

Could Iron Homeostasis Be a Therapeutic Target in Diffuse Large B-Cell Lymphoma?

Exploring the Combination of PD-1 and CDK9 Inhibitors in Hematologic Cancers

CD20-CD3 Bispecific Antibody Plus Chemotherapy for High-Risk DLBCL

Axicabtagene Ciloleucel in High-Risk Large B-Cell Lymphoma: Primary Analysis of ZUMA-12

Phase II Study Results of Lisocabtagene Maraleucel in Large B-Cell Lymphoma: From a Nonuniversity Setting

Three Novel Regimens for Diffuse Large B-Cell Lymphoma: UNITY-NHL Study

FDA Brief: Priority Review for Lisocabtagene Maraleucel as Second-Line Therapy for LBCL

TP53 Alterations in Predicting Response to Immunotherapy for Large B-Cell Lymphoma

Using SHP1 Expression to Predict Response to Ibrutinib in Diffuse Large B-Cell Lymphoma

Parsaclisib in BTK Inhibitor–Naive Relapsed or Refractory Mantle Cell and Marginal Zone Lymphomas

Safety of Umbralisib in Treatment of Lymphomas Under Review by the FDA

FDA Approves Label Update to Axicabtagene Ciloleucel to Include Toxicity Management Strategy

Lisocabtagene Maraleucel Versus Chemotherapy in B-Cell Lymphoma: Interim Analysis of TRANSFORM Trial

FDA Brief: Bispecific CAR T-Cell Therapy Receives Fast Track Designation in DLBCL

Second-Line CAR T -Cell Therapy Versus Standard of Care in Large B-Cell Lymphoma: ZUMA-7 Trial

Phase IIb Trial of Umbralisib Plus Ublituximab in Marginal Zone Lymphoma

Long-Term Follow-Up of Maintenance Therapy Versus Retreatment With Rituximab for Follicular Lymphoma

CD19-Directed CAR T-Cell Therapy for Large B-Cell Lymphoma: 2-Year Follow-up Data

Polatuzumab Vedotin-piiq Combination Regimen in Newly Diagnosed DLBCL: POLARIX Trial

Chemotherapy-Free Regimen Under Study in Resistant Diffuse Large B-Cell Lymphoma

Preliminary Study Data on Glofitamab Plus Polatuzumab Vedotin-piiq in DLBCL

Naratuximab Emtansine Plus Rituximab in B-Cell Non-Hodgkin Lymphomas

CD19-Derived CAR Natural Killer Cell Therapy in Resistant B-Cell Lymphoma

Next-Generation BTK Inhibitor Under Study in Mantle Cell Lymphoma